Gain Control of Bleeding
In the Treatment of Congenital Fibrinogen Deficiency (CFD)
Fibryga is a human fibrinogen indicated for the treatment of acute bleeding episodes in adults and children with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.1
Fibryga is not indicated for dysfibrinogenemia.1
Fibryga is a
purified, virus-inactivated and nanofiltered (20 nm) human
Effective bleeding control
For the first time in this rare disease setting, robust analysis methodology using objective efficacy criteria was implemented, demonstrating the hemostatic efficacy of fibryga.2
- Fibryga full Prescribing Information. Paramus, NJ: Octapharma; rev 2020.
- Lissitchkov T, Madan B, Djambas Khayat C, et al. Efficacy and safety of a new human fibrinogen concentrate in patients with congenital fibrinogen deficiency: an interim analysis of a Phase III trial. Transfusion. 2018;58:413-422.